Regeneron Pharmaceuticals, Inc. Earnings

Regeneron Pharmaceuticals, Inc.’s revenue jumped 3.62% since last year same period to $3675.6Mn in the Q2 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 21.36% jump in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit fell -2.84% since last year same period to $1391.6Mn in the Q2 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 72.08% jump in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -6.24% since last year same period to 37.86% in the Q2 2025. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 41.79% jump in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q2 2025 earnings stands at 14.86.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 9.65 - a 13.13% jump from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 9.65.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Regeneron Pharmaceuticals, Inc. declared 0.88 dividend per share during the earnings announcement for Q3 2025.